Kestra Medical Technologies (NASDAQ:KMTS) Research Coverage Started at Oppenheimer

Oppenheimer started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued a market perform rating on the stock.

Several other brokerages have also recently weighed in on KMTS. The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. BTIG Research raised their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $21.57 on Tuesday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $22.30 and a two-hundred day simple moving average of $22.57. Kestra Medical Technologies has a 12 month low of $14.10 and a 12 month high of $30.00. The firm has a market capitalization of $1.26 billion, a PE ratio of -8.91 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Analysts forecast that Kestra Medical Technologies will post -2.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Seven Grand Managers LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter worth about $2,652,000. Eventide Asset Management LLC boosted its stake in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter valued at approximately $9,282,000. UBS Group AG grew its position in shares of Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after acquiring an additional 69,908 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after purchasing an additional 28,573 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.